{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:43:06Z","timestamp":1791477786704,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prospective cohort study design was implemented. The data were collected from September 2016 \u2013 May 2019. Systematic random sampling was used to select the study participants. Baseline data were collected before the patient starts DOTS, the sign of liver toxicity was assessed every week. Tuberculosis treatment outcomes and WHO clinical stage was recorded at the end of 6th months. Descriptive statistics were used to estimate the prevalence of hepatitis B, hepatitis C viral infections and their effect on tuberculosis treatment outcomes. Binary logistic regression was used to identify the determinants of hepatitis B and C infections. The Kaplan Meier survival curve was used to estimate the survival of tuberculosis patient and Cox regression was used to identify the predictors of drug-induced hepatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3537 tuberculosis patients were followed. The prevalence of hepatitis B and C viral infection among tuberculosis patients were 15.1 and 17.3% respectively. Hepatitis B viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. Hepatitis C viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. The incidence density for liver toxicity among tuberculosis patients was 843\/15707 person-months and liver toxicity was determined by HIV, Hepatitis B, Hepatitis C, the severity of tuberculosis and chronic illnesses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Decision-makers should consider incorporating screening for hepatitis B and C viral infection during tuberculosis treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-020-01385-z","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T09:03:01Z","timestamp":1602493381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9251-3337","authenticated-orcid":false,"given":"Berhanu Elfu","family":"Feleke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teferi Elfu","family":"Feleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondimu Gebrekiros","family":"Adane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Girma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"1385_CR1","unstructured":"WHO. What is Hepatitis? Switzerland. Geneva: World Health Organization; 2019."},{"issue":"9959","key":"1385_CR2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Trepo","year":"2014","unstructured":"Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053\u201363.","journal-title":"Lancet"},{"key":"1385_CR3","doi-asserted-by":"crossref","unstructured":"Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection. Hepatitis B virus in human diseases. Switzerland: Springer; 2016. p. 187\u2013203.","DOI":"10.1007\/978-3-319-22330-8_9"},{"issue":"4","key":"1385_CR4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcv.2012.04.006","volume":"54","author":"RS Aires","year":"2012","unstructured":"Aires RS, Matos MA, Lopes CL, Teles SA, Kozlowski AG, Silva AM, et al. Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiania City, Brazil. J Clin Virol. 2012;54(4):327\u201331.","journal-title":"J Clin Virol"},{"issue":"34","key":"1385_CR5","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"A Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824\u201340.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1385_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1385_CR7","volume-title":"Global Tuberculosis Report 2018","author":"WHO","year":"2018","unstructured":"WHO. Global Tuberculosis Report 2018. Swetherland: World Health Organization; 2018."},{"issue":"11","key":"1385_CR8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.5588\/ijtld.15.0743","volume":"20","author":"LM Iglecias","year":"2016","unstructured":"Iglecias LM, Puga MA, Pompilio MA, Teles SA, Croda J, Lima LA, et al. Epidemiological study of hepatitis B virus among prisoners with active tuberculosis in Central Brazil. Int J Tuberc Lung Dis. 2016;20(11):1509\u201315.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"1385_CR9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4254\/wjh.v4.i3.74","volume":"4","author":"E Franco","year":"2012","unstructured":"Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):74.","journal-title":"World J Hepatol"},{"key":"1385_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijid.2014.06.020","volume":"28","author":"P Mo","year":"2014","unstructured":"Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014;28:95\u2013100.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"1385_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S2222-1808(15)60989-6","volume":"6","author":"B Farhoudi","year":"2016","unstructured":"Farhoudi B, SeyedAlinaghi S, Mohraz M, Hosseini M, Farnia M. Tuberculosis, hepatitis C and hepatitis B co-infections in patients with HIV in the great Tehran prison, Iran. Asian Pac J Trop Dis. 2016;6(1):82\u20133.","journal-title":"Asian Pac J Trop Dis"},{"issue":"10","key":"1385_CR12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.5588\/ijtld.10.0636","volume":"15","author":"NR Reis","year":"2011","unstructured":"Reis NR, Lopes CL, Teles SA, Matos MA, Carneiro MA, Marinho TA, et al. Hepatitis C virus infection in patients with tuberculosis in Central Brazil. Int J Tuberc Lung Dis. 2011;15(10):1397\u2013402.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1385_CR13","first-page":"945","volume":"29","author":"M Behzadifar","year":"2019","unstructured":"Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of hepatitis C virus in tuberculosis patients: a systematic review and meta-analysis. Ethiop J Health Sci. 2019;29(1):945\u201356.","journal-title":"Ethiop J Health Sci"},{"issue":"6","key":"1385_CR14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jmv.24432","volume":"88","author":"C Araujo-Mariz","year":"2016","unstructured":"Araujo-Mariz C, Lopes EP, Ximenes RA, Lacerda HR, Miranda-Filho DB, Montarroyos UR, et al. Serological markers of hepatitis B and C in patients with HIV\/AIDS and active tuberculosis. J Med Virol. 2016;88(6):996\u20131002.","journal-title":"J Med Virol"},{"issue":"12","key":"1385_CR15","doi-asserted-by":"crossref","first-page":"e0226890","DOI":"10.1371\/journal.pone.0226890","volume":"14","author":"AE Woldegiorgis","year":"2019","unstructured":"Woldegiorgis AE, Erku W, Medhin G, Berhe N, Legesse M. Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia. PloS one. 2019;14(12):e0226890.","journal-title":"PloS one"},{"issue":"1","key":"1385_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12985-017-0696-6","volume":"14","author":"B Abera","year":"2017","unstructured":"Abera B, Adem Y, Yimer M, Mulu W, Zenebe Y, Mekonnen Z. Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, Northwest Ethiopia. Virol J. 2017;14(1):21.","journal-title":"Virol J"},{"key":"1385_CR17","unstructured":"Organization WH. Global tuberculosis report 2013. Switzerland: World Health Organization; 2013."},{"issue":"6","key":"1385_CR18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5588\/ijtld.13.0417","volume":"18","author":"A Kebede","year":"2014","unstructured":"Kebede A, Alebachew Z, Tsegaye F, Lemma E, Abebe A, Agonafir M, et al. The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011. Int J Tuberc Lung Dis. 2014;18(6):635\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1385_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12879-018-3192-8","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Bao D, Gu L, Gu Y, Zhou L, Gao Z, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):295.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1385_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.gastrohep.2018.03.003","volume":"42","author":"M Pedrosa","year":"2019","unstructured":"Pedrosa M, Nogales S, Vergara M, Miquel M, Casas M, Dalmau B, et al. Reactivation of peritoneal and pleural tuberculosis during hepatitis C treatment with direct-acting antivirals. Gastroenterol Hepatol. 2019;42(3):174\u20135.","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"1385_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bjid.2015.12.003","volume":"20","author":"SN de Oliveira Uehara","year":"2016","unstructured":"de Oliveira Uehara SN, Emori CT, Perez RM, Mendes-Correa MC. de Souza Paiva Ferreira a, de Castro Amaral Feldner AC, et al. high incidence of tuberculosis in patients treated for hepatitis C chronic infection. Braz J Infect Dis. 2016;20(2):205\u20139.","journal-title":"Braz J Infect Dis"},{"issue":"33","key":"1385_CR22","volume":"94","author":"PH Wu","year":"2015","unstructured":"Wu PH, Lin YT, Hsieh KP, Chuang HY, Sheu CC. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a Nationwide population-based study. Medicine (Baltimore). 2015;94(33):e1328.","journal-title":"Medicine (Baltimore)"},{"key":"1385_CR23","unstructured":"Ladep NG, Agbaji OO, Agaba PA, Muazu A, Ugoagwu P, Imade G, et al. Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa. J AIDS Clin Res. 2013;2013(Suppl 3):1-7."},{"key":"1385_CR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","volume":"16","author":"WS Kim","year":"2016","unstructured":"Kim WS, Lee SS, Lee CM, Kim HJ, Ha CY, Kim HJ, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1385_CR25","first-page":"78","volume":"11","author":"E Pukenyte","year":"2007","unstructured":"Pukenyte E, Lescure F, Rey D, Rabaud C, Hoen B, Chavanet P, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007;11(1):78\u201384.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1385_CR26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijmyco.2015.10.002","volume":"5","author":"W Abera","year":"2016","unstructured":"Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro zone, South Ethiopia: a cohort study. Int J Mycobacteriol. 2016;5(1):14\u201320.","journal-title":"Int J Mycobacteriol"},{"issue":"12","key":"1385_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083892","volume":"8","author":"N Lomtadze","year":"2013","unstructured":"Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892.","journal-title":"PLoS One"},{"issue":"8","key":"1385_CR28","first-page":"585","volume":"22","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, Ma S, Tan D, Lu M. A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy. Zhonghua Gan Zang Bing Za Zhi. 2014;22(8):585\u20139.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"1","key":"1385_CR29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","volume":"3","author":"E Hughes","year":"2016","unstructured":"Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40\u20138.","journal-title":"Lancet Psychiatry"},{"key":"1385_CR30","volume-title":"HIV and viral hepatitis. South Carolina State Documents Depository","author":"Control CfD, Prevention","year":"2017","unstructured":"Control CfD, Prevention. HIV and viral hepatitis. South Carolina State Documents Depository. 2017."},{"issue":"2","key":"1385_CR31","doi-asserted-by":"crossref","first-page":"e1005374","DOI":"10.1371\/journal.ppat.1005374","volume":"12","author":"LG vom Steeg","year":"2016","unstructured":"vom Steeg LG, Klein SL. SeXX matters in infectious disease pathogenesis. PLoS pathogens. 2016;12(2):e1005374.","journal-title":"PLoS pathogens"},{"issue":"8","key":"1385_CR32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/jgh.12934","volume":"30","author":"SH Wang","year":"2015","unstructured":"Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: mechanisms of sex hormones. J Gastroenterol Hepatol. 2015;30(8):1237\u201345.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"1385_CR33","first-page":"8195","volume":"6","author":"M Shakour","year":"2018","unstructured":"Shakour M, Salehi K, Yamani N. Reproductive health need assessment of adolescent boys and girls during puberty: a qualitative study. Int J Pediatr. 2018;6(9):8195\u2013205.","journal-title":"Int J Pediatr"},{"issue":"1","key":"1385_CR34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/mi.2015.51","volume":"9","author":"KB Arnold","year":"2016","unstructured":"Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2016;9(1):194.","journal-title":"Mucosal Immunol"},{"issue":"5","key":"1385_CR35","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ki.2014.363","volume":"87","author":"Y-C Chen","year":"2015","unstructured":"Chen Y-C, Su Y-C, Li C-Y, Wu C-P, Lee M-S. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2015;87(5):1030\u20138.","journal-title":"Kidney Int"},{"issue":"12","key":"1385_CR36","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","volume":"60","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci. 2015;60(12):3801\u201313.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1385_CR37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-015-0106-5","volume":"16","author":"Y-C Chen","year":"2015","unstructured":"Chen Y-C, Su Y-C, Li C-Y, Hung S-K. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC Nephrol. 2015;16(1):110.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1385_CR38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12913-016-1484-5","volume":"16","author":"MW Huygens","year":"2016","unstructured":"Huygens MW, Vermeulen J, Swinkels IC, Friele RD, Van Schayck OC, De Witte LP. Expectations and needs of patients with a chronic disease toward self-management and eHealth for self-management purposes. BMC Health Serv Res. 2016;16(1):232.","journal-title":"BMC Health Serv Res"},{"key":"1385_CR39","doi-asserted-by":"crossref","unstructured":"Krajden M, Cook DA, Wong S, Yu A, Butt ZA, Rossi C, et al. What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada. Int J Drug Policy. 2019;2019:5.","DOI":"10.1016\/j.drugpo.2019.06.003"},{"issue":"11","key":"1385_CR40","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3748\/wjg.v24.i11.1216","volume":"24","author":"M Binka","year":"2018","unstructured":"Binka M, Butt ZA, Wong S, Chong M, Buxton JA, Chapinal N, et al. Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada. World J Gastroenterol. 2018;24(11):1216.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1385_CR41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s10461-014-0896-7","volume":"19","author":"CW Kahler","year":"2015","unstructured":"Kahler CW, Wray TB, Pantalone DW, Kruis RD, Mastroleo NR, Monti PM, et al. Daily associations between alcohol use and unprotected anal sex among heavy drinking HIV-positive men who have sex with men. AIDS Behav. 2015;19(3):422\u201330.","journal-title":"AIDS Behav"},{"issue":"7","key":"1385_CR42","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"1385_CR43","doi-asserted-by":"crossref","unstructured":"Al-Khazraji A, Alkhawam H, Garrido B. Id: 30: hepatitis b virus reactivation in an inactive carrier of chronic HBV AFTER the initiation of treatment for TIBERCULOSIS. Great Britain: BMJ Publishing Group Limited; 2016.","DOI":"10.1136\/jim-2016-000120.56"},{"issue":"12","key":"1385_CR44","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/ajg.2016.422","volume":"111","author":"AA Pillai","year":"2016","unstructured":"Pillai AA, Anania FA, Pearlman BL. Caution: reactivation of hepatitis B during hepatitis C treatment with direct-acting antiviral therapy. Am J Gastroenterol. 2016;111(12):1854.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1385_CR45","doi-asserted-by":"crossref","first-page":"20944","DOI":"10.7448\/IAS.19.1.20944","volume":"19","author":"N Petersdorf","year":"2016","unstructured":"Petersdorf N, Ross JM, Weiss HA, Barnabas RV, Wasserheit JN, HCV and HIV Transmission Working Group, et al. Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy. J Int AIDS Soc. 2016;19(1):20944.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"1385_CR46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4049\/jimmunol.162.2.931","volume":"162","author":"MK Large","year":"1999","unstructured":"Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 1999;162(2):931\u20138.","journal-title":"J Immunol"},{"issue":"17","key":"1385_CR47","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci. 2004;101(17):6669\u201374.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1385_CR48","first-page":"163","volume":"17","author":"H Khalili","year":"2015","unstructured":"Khalili H, Dashti-Khavidaki S, Rasoolinejad M, Rezaie L, Etminani M. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU J Pharm Sci. 2015;17(3):163\u20137.","journal-title":"DARU J Pharm Sci"},{"issue":"10","key":"1385_CR49","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","volume":"21","author":"CJ Hoffmann","year":"2007","unstructured":"Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids. 2007;21(10):1301\u20138.","journal-title":"Aids."},{"issue":"1","key":"1385_CR50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12879-017-2598-z","volume":"17","author":"E Osei","year":"2017","unstructured":"Osei E, Der J, Owusu R, Kofie P, Axame WK. The burden of HIV on tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for tuberculosis control. BMC Infect Dis. 2017;17(1):504.","journal-title":"BMC Infect Dis"},{"key":"1385_CR51","doi-asserted-by":"crossref","unstructured":"Teschke R. Hepatotoxicity: molecular mechanisms and pathophysiology. Switzerland: Multidisciplinary Digital Publishing Institute; 2019.","DOI":"10.3390\/ijms20010211"},{"issue":"3","key":"1385_CR52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40495-018-0131-8","volume":"4","author":"Y Bao","year":"2018","unstructured":"Bao Y, Ma X, Rasmussen TP, Zhong X-B. Genetic Variations associated with anti-tuberculosis drug-induced liver injury. Curr Pharmacol Rep. 2018;4(3):171\u201381.","journal-title":"Curr Pharmacol Rep"},{"issue":"12","key":"1385_CR53","first-page":"1499","volume":"8","author":"A Fernandez-Villar","year":"2004","unstructured":"Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499\u2013505.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"1385_CR54","first-page":"1","volume":"33","author":"M Tipayamongkholgul","year":"2016","unstructured":"Tipayamongkholgul M, Marin W, Sujirarat D, Pokaew P, Pungrassami P, et al. Trop Biomed. 2016;33(1):1\u20137.","journal-title":"Trop Biomed"},{"issue":"4","key":"1385_CR55","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","volume":"101","author":"M Mosedale","year":"2017","unstructured":"Mosedale M, Watkins PB. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1385_CR56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","volume":"139","author":"K Fisher","year":"2015","unstructured":"Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139(7):876\u201387.","journal-title":"Arch Pathol Lab Med"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T14:43:07Z","timestamp":1696862587000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01385-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical clearance was obtained from Bahir Dar University ethical review board. Permission letter was obtained from Amhara national regional, state health bureau ethics committee and the respective health facility heads. Written informed consent was obtained from each study participant. Study participants the right to withdraw from this research at any point was respected. The confidentiality of the data was kept at all stages. Study participants with hepatitis B or hepatitis C viral infections were linked to the available services in the health facilities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}